Avid prepares to present findings of Alzheimer's study

06/23/2010 | New York Times (tiered subscription model), The

Avid Radiopharmaceuticals, a company that developed fluoride 18-based dyes for use in PET scans of amyloid plaques, said it has received the results of a study using its dye to determine whether Alzheimer's disease diagnosed through a PET scan correlates with that determined through a brain autopsy. The results, to be presented at the Alzheimer's Association meeting next month, will "have a big impact on Alzheimer's disease," said Dr. Daniel Skovronsky, founder of the company.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR